IRO compound for use in a procedure for therapeutically treating a mammal presenting a disease that has an autoimmune or inflammatory component, said method comprising administering to the mammal an IRO compound having the structure 5'-Nm-N3N2N1CGN1N2N3-Nm -3 ': in which: CG is an oligonucleotide motif that is CpG, C * pG, C * pG * or CpG *, in which C is cytosine, C * is a pyrimidine nucleotide derivative that is a pyrimidine nucleotide that has a base which is not cytosine, thymine or uracil and / or a sugar that is not ribose or 2'-deoxyribose and may be present in the skeleton of an oligonucleotide, G is guanosine, and G * is a nucleotide derivative of purine that is a nucleotide purine having a base that is not guanine or adenine and / or a sugar that is not ribose or 2'-deoxyribose and may be present in the skeleton of an oligonucleotide； N1-N3 at each occurrence, is independently i) a nucleotide, ii) a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine or uracil and / or a sugar that does not it is ribose or 2'-deoxyribose and can be present in the skeleton of an oligonucleotide, or iii) a non-nucleotide bond provided that at least one N1-N3 is a nucleotide derivative or a non-nucleotide bond that suppresses the activity of the oligonucleotide motif ； N1-N3, at each occurrence, is independently i) a nucleotide, ii) a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine or uracil and / or a sugar that it is not ribose or 2'-deoxyribose and may be present in the skeleton of an oligonucleotide, or iii) a non-nucleotide bond； Nm and Nm, at each occurrence, is independently a nucleotide, nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine or uracil and / or a sugar that is not ribose or 2 '-deoxyribose and may be present in the skeleton of
